Abeona Therapeutics (NASDAQ: ABEO)
Abeona Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Abeona Therapeutics Company Info
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.
News & Analysis
Here's Why Abeona Therapeutics Fell as Much as 43.8% Today
The small-cap company announced the pricing of a public stock offering.
3 Small-Cap Biotech Stocks to Keep on Your Radar
Small market caps. Big opportunities.
Here's Why Abeona Therapeutics Stock Dropped 12% Today
A clinical trial update for AB-102 didn't go far enough.
3 Biotech Stocks That Soared This Week: Are They Buys?
Can these red-hot biotech stocks keep the momentum going?
Why Abeona Therapeutics Jumped 14% on Wednesday
Positive clinical trial data from a single patient sends shares soaring.
Here's Why Abeona Therapeutics Inc. Stock Spiked Today
The red-hot gene therapy start-up took a big step towards its first potential new drug application.
Why Abeona Therapeutics Inc Stock Jumped Higher Today
An analyst started coverage at a buy, but there's more that long-term investors should be focused on.
3 Biotech Stocks That Skyrocketed This Week
Abeona, Sangamo, and Juno ride the huge wave resulting from Gilead Sciences' acquisition of Kite Pharma.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.